Meglumine antimoniate indications and usage

Revision as of 03:40, 7 January 2014 by Gerald Chi (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Meglumine Antimoniate
GLUCANTIM® WHO Prescribing Information
Description
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Dosage and Administration
How Supplied

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Indications and Usage

Treatment of:

  • Visceral leishmaniasis
  • Cutaneous leishmaniasis (except for L. aethiopica infections, which are unresponsive)
  • Diffuse cutaneous leishmaniasis due to L. amazonensis
  • Cutaneous and mucocutaneous leishmaniasis due to L. braziliensis.[1]

References

  1. "WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate".

Adapted from the FDA Package Insert.